NEW YORK, August 06, 2021 (GLOBE NEWSWIRE) – NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a program titled “The Cardiovascular Disease Drug Market Offers Compelling Potential for Early Drivers, Innovators in Space.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast
To read the full editorial, visit: https://nnw.fm/dJwHD
Controlling blood pressure is essential for health. High blood pressure is a leading or contributing cause of death in nearly 500,000 deaths per year, and high blood pressure can double the risk of heart attack and quadruple the risk of stroke, in addition to increasing the likelihood of stroke. heart failure, vision loss, kidney disease, dementia, peripheral artery disease and more. And it’s not just an “old person” problem; nearly one in four adults aged 20 to 44 has high blood pressure. What’s more, high blood pressure costs the United States about $ 131 billion each year. The good news? The disease can be managed – and even cured – with effective treatment. . . .
Lexaria Bioscience Corp. (NASDAQ: LEXX) may be at the forefront of some of the exciting innovations in space. The Kelowna, British Columbia-based company developed and patented its DehydraTECH technology, a drug delivery platform to increase the rate of onset, bioavailability and potency of drugs.
About Lexaria Bioscience Corp.
Lexaria Bioscience’s proprietary drug delivery technology, DehydraTECH (TM), improves the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing blood pressure. efficiency of liposoluble active molecules, thus reducing the overall dosage. The company’s technology can be applied to many different ingestible product formats, including food, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated its ability to increase the bioabsorption of cannabinoids and nicotine up to 5 to 10 times, reduce the time to onset from one to two hours to a few minutes and mask tastes. unwanted; the technology should be further evaluated for bioactive molecules given orally, including antiviral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to several companies, including a leading tobacco producer in the world, for the development of smokeless and oral-based nicotine products and for use in industries that produce cannabinoid drinks, cannabinoid products. edible and oral products. Lexaria operates an in-house licensed research laboratory and has a strong intellectual property portfolio with 21 granted patents and over 50 patents pending worldwide.
For more information about the company, please visit www.LexariaBioscience.com.
NOTICE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s press room at https://ibn.fm/LEXX
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize company news and insights, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of communications solutions from company. As a multi-faceted financial news and content distribution company with a large team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies who wish to reach a large investor audience. , consumers, journalists and the general public. NNW has a growing distribution network of over 5,000 key syndication outlets across the country. By eliminating the information overload in today’s market, NNW brings unmatched visibility, recognition and brand awareness to its clients. NNW is where news, content and information converge.
To receive SMS alerts from NetworkNewsWire, send “STOCKS” to 77948 (US mobile phones only)
For more information, please visit https://www.NetworkNewsWire.com
New York, New York
NetworkNewsWire is part of InvestorBrandNetwork